TECENTRIQ® (atezolizumab) clinical trials overview in 1L ES‑SCLC
IMforte (TECENTRIQ + lurbinectedin) is the first and only FDA‑approved combination for maintenance treatment in first‑line extensive‑stage small cell lung cancer.
This webpage summarizes the clinical development of TECENTRIQ (atezolizumab) in extensive‑stage small cell lung cancer (ES‑SCLC), highlighting the IMforte trial that established the combination of TECENTRIQ and lurbinectedin as the first FDA‑approved maintenance therapy for patients who received first‑line induction. It also provides detailed safety information on immune‑mediated adverse events seen with TECENTRIQ, including pneumonitis, colitis, hepatitis, endocrine disorders, and infusion‑related reactions.
The information is crucial for clinicians and patients, as it outlines an FDA‑approved therapeutic option for ES‑SCLC and provides a comprehensive safety profile that guides monitoring and management of treatment‑related toxicities.
Bizonyítékszint: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.
Kapcsolódó jelek
- Extensive-stage Small Cell Lung Cancer - Gallipoli Medical Research
- EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapy
- Treatment of Small‑Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline
- Does maintenance/consolidation chemotherapy have a role in the management of small cell lung cancer (SCLC)? A metaanalysis of the published controlled trials.
- Cancer's protective shield: Blocking a signaling pathway could make small cell lung tumors visible to T cells